Common use of Material Changes Clause in Contracts

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SEC, there will not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development that could reasonably be expected to cause a Material Adverse Effect.

Appears in 33 contracts

Sources: At the Market Issuance Sales Agreement (Alzamend Neuro, Inc.), At the Market Issuance Sales Agreement (ENDRA Life Sciences Inc.), At the Market Issuance Sales Agreement (Auddia Inc.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, Change or any development that could reasonably be expected to cause result in a Material Adverse EffectChange.

Appears in 19 contracts

Sources: Sales Agreement (Dianthus Therapeutics, Inc. /DE/), Common Stock Sales Agreement (Bridgeline Digital, Inc.), Sales Agreement (Spyre Therapeutics, Inc.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development that could reasonably be expected to cause a Material Adverse Effect.

Appears in 19 contracts

Sources: Capital on Demand Sales Agreement (Cassava Sciences Inc), At Market Issuance Sales Agreement (Aeterna Zentaris Inc.), At Market Issuance Sales Agreement (Aeterna Zentaris Inc.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SEC, there will not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development that could would reasonably be expected to cause a Material Adverse Effect.

Appears in 11 contracts

Sources: At the Market Issuance Sales Agreement (Youxin Technology LTD), At the Market Issuance Sales Agreement (HiTek Global Inc.), At the Market Issuance Sales Agreement (Expion360 Inc.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development that could would reasonably be expected to cause a Material Adverse Effect.

Appears in 7 contracts

Sources: At the Market Issuance Sales Agreement (Emerald Oil, Inc.), At the Market Issuance Sales Agreement (Emerald Oil, Inc.), At Market Issuance Sales Agreement (Echo Therapeutics, Inc.)

Material Changes. Except as contemplated in the Registration Statement and the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could reasonably be expected to cause a Material Adverse Effect.

Appears in 7 contracts

Sources: At the Market Issuance Sales Agreement (Houston American Energy Corp), At the Market Issuance Sales Agreement (Soluna Holdings, Inc), At the Market Issuance Sales Agreement (Houston American Energy Corp)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission and incorporated by reference in the Prospectus, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any or any Material Adverse Effect, Effect or any development that could reasonably be expected to cause result in a Material Adverse Effect.

Appears in 7 contracts

Sources: Sales Agreement (AGNC Investment Corp.), Sales Agreement (MTGE Investment Corp.), Sales Agreement (MTGE Investment Corp.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, Effect or any development that could reasonably be expected to cause result in a Material Adverse Effect.

Appears in 6 contracts

Sources: Sales Agreement (Geron Corp), Sales Agreement (Revance Therapeutics, Inc.), Sales Agreement (Revance Therapeutics, Inc.)

Material Changes. Except as contemplated in the Prospectus, Prospectus or disclosed in the Company’s reports filed with the SEC, there will not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, Effect or any development that could would reasonably be expected to cause a Material Adverse Effect.

Appears in 5 contracts

Sources: At the Market Issuance Sales Agreement (VisionWave Holdings, Inc.), At the Market Issuance Sales Agreement (Sunshine Biopharma Inc.), At the Market Issuance Sales Agreement (Inno Holdings Inc.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission and incorporated by reference in the Prospectus, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, Effect or any development that could reasonably be expected to cause result in a Material Adverse Effect.

Appears in 4 contracts

Sources: Sales Agreement (AGNC Investment Corp.), Sales Agreement (AGNC Investment Corp.), Sales Agreement (AGNC Investment Corp.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could would reasonably be expected to cause a Material Adverse Effect.

Appears in 3 contracts

Sources: At Market Issuance Sales Agreement (Fortress Biotech, Inc.), At Market Issuance Sales Agreement (Coronado Biosciences Inc), At Market Issuance Sales Agreement (Coronado Biosciences Inc)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse changeMaterial Adverse Change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, Change or any development that could would reasonably be expected to cause result in a Material Adverse EffectChange.

Appears in 3 contracts

Sources: Sales Agreement (Revolution Medicines, Inc.), Sales Agreement (Revolution Medicines, Inc.), Sales Agreement (Revolution Medicines, Inc.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, change in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could reasonably be expected to cause a Material Adverse Effect.

Appears in 3 contracts

Sources: At Market Issuance Sales Agreement (Geron Corp), At Market Issuance Sales Agreement (Geron Corp), At Market Issuance Sales Agreement (Geron Corp)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, Change or any development that could would reasonably be expected to cause result in a Material Adverse EffectChange.

Appears in 3 contracts

Sources: Sales Agreement (Revolution Medicines, Inc.), Sales Agreement (Savara Inc), Sales Agreement (Oncothyreon Inc.)

Material Changes. Except as contemplated in the ProspectusProspectuses, or disclosed in the Company’s 's reports filed with the SECCommission or Canadian Qualifying Authorities, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, Change or any development that could reasonably be expected to cause result in a Material Adverse EffectChange.

Appears in 2 contracts

Sources: Equity Distribution Agreement (High Tide Inc.), Equity Distribution Agreement (High Tide Inc.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s 's reports filed with the SECCommission and incorporated by reference in the Prospectus, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any or any Material Adverse Effect, Effect or any development that could reasonably be expected to cause result in a Material Adverse Effect.

Appears in 2 contracts

Sources: Sales Agreement (American Capital Agency Corp), Sales Agreement (American Capital Agency Corp)

Material Changes. Except as contemplated in the Prospectus, Prospectus or disclosed in the Company’s reports filed with the SEC, there will not have been any material adverse change, on a consolidated basis, in the authorized share capital stock of the Company or any Material Adverse Effect, Effect or any development that could would reasonably be expected to cause a Material Adverse Effect.

Appears in 2 contracts

Sources: At the Market Issuance Sales Agreement (Haoxi Health Technology LTD), At the Market Issuance Sales Agreement (Innovation Beverage Group LTD)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development that could reasonably be expected to cause a Material Adverse Effect.. 

Appears in 2 contracts

Sources: Sales Agreement (Cassava Sciences Inc), Capital on Demand Sales Agreement (Pain Therapeutics Inc)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, change in the authorized capital stock of the Company or any Material Adverse Effect, Change or any development that could reasonably be expected to cause result in a Material Adverse EffectChange.

Appears in 2 contracts

Sources: Sales Agreement (TSR Inc), Sales Agreement (TSR Inc)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s 's reports filed with the SEC, there will not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development that could would reasonably be expected to cause a Material Adverse Effect.

Appears in 1 contract

Sources: At the Market Issuance Sales Agreement (Flora Growth Corp.)

Material Changes. Except as contemplated in the Registration Statement, Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development that could reasonably be expected to cause a Material Adverse Effect.

Appears in 1 contract

Sources: Sales Agreement (HighPeak Energy, Inc.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, change in the authorized capital stock of the Company or any Material Adverse Effect, or any development that could would reasonably be expected to cause a Material Adverse Effect., that in each case, is so material as to make it impracticable or inadvisable to proceed with the offering of the Placement Shares on the terms and in the manner contemplated in the Prospectus

Appears in 1 contract

Sources: At the Market Issuance Sales Agreement (Kalobios Pharmaceuticals Inc)

Material Changes. Except as contemplated in the U.S. Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development that could reasonably be expected to cause a Material Adverse Effect.

Appears in 1 contract

Sources: At Market Issuance Sales Agreement (Aeterna Zentaris Inc.)

Material Changes. Except as contemplated in the Prospectus, Registration Statement or disclosed in the Company’s reports filed with the SECSEC and incorporated by reference into the Registration Statement, there will has not have been any material adverse change, on a consolidated basis, change in the Company’s authorized capital stock of the Company or any Material Adverse Effect, Effect or any development that could reasonably be expected to cause a Material Adverse EffectEffect on the Company.

Appears in 1 contract

Sources: Sale Agreement (Touchpoint Group Holdings Inc.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, change in the authorized capital stock of the Company or any Material Adverse Effect, or any development that could reasonably be expected to cause a Material Adverse Effect.,

Appears in 1 contract

Sources: Sales Agreement (Tanzanian Gold Corp)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the CompanyCompany and Parent’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company and the Parent or any Material Adverse Effect, or any development that could reasonably be expected to cause a Material Adverse Effect.

Appears in 1 contract

Sources: At the Market Issuance Sales Agreement (Gastar Exploration USA, Inc.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s 's reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development in the business or affairs of the Company that could reasonably be expected to cause a Material Adverse Effect.

Appears in 1 contract

Sources: At the Market Issuance Sales Agreement (Microvision, Inc.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SEC, there will not have been any material adverse change, on a consolidated basis, in the authorized share capital stock of the Company or any Material Adverse Effect, or any development that could would reasonably be expected to cause a Material Adverse Effect.

Appears in 1 contract

Sources: At the Market Issuance Sales Agreement (SciSparc Ltd.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse changeMaterial Adverse Change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse EffectChange, or any development that could reasonably be expected to cause a Material Adverse Effect.a

Appears in 1 contract

Sources: Sales Agreement (BGC Partners, Inc.)

Material Changes. Except as contemplated in the U.S. Prospectus, or disclosed in the Company’s 's reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development that could reasonably be expected to cause a Material Adverse Effect.

Appears in 1 contract

Sources: At Market Issuance Sales Agreement (Aeterna Zentaris Inc.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, Effect or any development that could would reasonably be expected to cause result in a Material Adverse Effect.. US-DOCS\111349286.7

Appears in 1 contract

Sources: Common Stock Sales Agreement (Allogene Therapeutics, Inc.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SEC, there will not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, or any development that could would reasonably be expected to cause a Material Adverse Effect.

Appears in 1 contract

Sources: At the Market Issuance Sales Agreement (Medigus Ltd.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, change in the authorized capital stock of the Company or any Material Adverse Effect, Effect or any development that could reasonably be expected to would cause a Company Material Adverse Effect.

Appears in 1 contract

Sources: Sales Agreement (Origin Agritech LTD)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect, Effect or any development that could would reasonably be expected to cause result in a Material Adverse Effect.

Appears in 1 contract

Sources: Sales Agreement (Allogene Therapeutics, Inc.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, change in the authorized capital stock of the Company or any Material Adverse Effect, Effect or any development that could reasonably be expected to would cause a Material Adverse Effect., or a downgrading in or withdrawal of the rating assigned to any of the Company’s securities (other than asset backed securities) by any rating organization or a public announcement by any rating organization that it has under surveillance

Appears in 1 contract

Sources: Sales Agreement (BigBear.ai Holdings, Inc.)

Material Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SECCommission, there will shall not have been any material adverse change, on a consolidated basis, change in the authorized capital stock of the Company or any Material Adverse Effect, Effect or any development that could reasonably be expected to cause a Material Adverse Effect.

Appears in 1 contract

Sources: Sales Agreement (Cerus Corp)